Zoledronic acid (Zometa) and denosumab for breast cancer: the complete patient guide

Zoledronic acid, sold under brand names such as Zometa, and denosumab, sold as Xgeva and Prolia, are bone-directed medicines. They do not attack cancer cells directly. Instead, they slow down the cells that break bone down, called osteoclasts, which helps keep bones strong. In breast cancer they are used in three main ways. First, when cancer has spread to the bones, they lower and delay the risk of fractures, spinal cord pressure, the need for radiotherapy or surgery to bone, and high blood calcium, and they can help with bone pain. Second, they protect bones from thinning caused by treatments that lower oestrogen, such as aromatase inhibitors or early menopause. Third, in women who are postmenopausal with early breast cancer, zoledronic acid given every six months for a few years slightly lowers the chance of cancer coming back in the bone and improves breast cancer survival. Denosumab has not shown that benefit, so it is not used for that purpose. Zoledronic acid is a short drip into a vein, while denosumab is a small injection under the skin. Both are generally well tolerated, but they need some precautions: a dental check before starting, calcium and vitamin D levels corrected, blood tests of kidney function and calcium, and good mouth care, because a rare side effect affects the jaw bone. Stopping denosumab also needs planning.

They protect bone, not destroy cancer

Their main role is keeping bones strong and preventing bone problems.

Different ways to give them

Zoledronic acid is a short drip. Denosumab is an injection under the skin.

Dental care matters

A dental check first and good mouth care lower the risk of jaw problems.

Bone-directed medicines are valuable, but their role is often misunderstood.

They do not shrink cancer in bone

In metastatic disease they protect the skeleton. Other treatments control the cancer itself.

Bone problems can still happen

They lower and delay the risk of fractures and other bone events, but cannot prevent them all.

The early breast cancer benefit is modest

For postmenopausal women, the gain is real but small, and it has not been shown before menopause unless the ovaries are switched off.

What this page cannot tell you

It cannot tell you whether you need one of these medicines or which one. Your oncologist will advise.

Most people have few problems, but some side effects are worth recognising early.

Flu-like symptoms

Aches, fever and tiredness for a day or two after the first zoledronic acid drip are common and usually settle.

Low calcium

More common with denosumab. Tingling around the mouth or fingers, or muscle cramps, should be reported.

Jaw problems

Rarely, jaw bone does not heal. Pain, swelling, loose teeth or exposed bone need prompt dental and medical review.

Rare effects

Unusual thigh fractures, eye inflammation and, with zoledronic acid, kidney changes.